Treatment for Tricuspid Valve Insufficiency

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mayo Clinic, Rochester, MN
Tricuspid Valve Insufficiency+1 More
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

Staging Classification of Severe Tricuspid Regurgitation Using Novel Cardiac Imaging Techniques

See full description

Eligible Conditions

  • Tricuspid Valve Insufficiency
  • Tricuspid valve incompetence

Treatment Effectiveness

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 1 secondary outcome in patients with Tricuspid Valve Insufficiency. Measurement will happen over the course of 1 year.

1 year
Correlation between severity of Tricuspid regurgitation by cardiac magnetic resonance imaging vs. elastography
Incidence of Severity of tricuspid regurgitation by cardiac magnetic resonance imaging

Trial Safety

Trial Design

0 Treatment Group

This trial requires 40 total participants across 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 1 year for reporting.

Who is running the study

Principal Investigator
M. A. A.
Prof. Mohamad Adnan Alkhouli, Professor of Medicine
Mayo Clinic

Closest Location

Mayo Clinic - Rochester, MN

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There is one eligibility criterion to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Moderate or more tricuspid regurgitation

Patient Q&A Section

What causes tricuspid valve incompetence?

"The underlying cause for the defect may appear very early and may not become evident until later in life. The pathogenesis can be divided in 2 phases. The first one is determined by the systolic blood pressure during the whole life and the second by the aging of the valve apparatus, which is more obvious." - Anonymous Online Contributor

Unverified Answer

Can tricuspid valve incompetence be cured?

"Tricuspid valve incompetence responds well to surgical repair performed within the first 4 years after acute onset. Tricuspid valve replacement is unnecessary in the long term if the patient is free from symptoms." - Anonymous Online Contributor

Unverified Answer

How many people get tricuspid valve incompetence a year in the United States?

"Approximately 25 million people have a tricuspid valve that is mildly or mildly to severely dysfunctional a year in the United States. It is clear that, even a small number of people who have an anatomically abnormal heart valve can have significant symptoms and signs of heart failure, with increased risk of death." - Anonymous Online Contributor

Unverified Answer

What are the signs of tricuspid valve incompetence?

"The clinical assessment of cardiac murmurs should be performed with the clinical history in mind. All patients with mitral insufficiency with signs of right heart failure should have tricuspid echocardiography." - Anonymous Online Contributor

Unverified Answer

What is tricuspid valve incompetence?

"Tricuspid regurgitation by echocardiography remains widely undertreated. However, despite its known association with significant cardiac dysfunction, the majority of patients with tricuspid regurgitation do not undergo treatment. In patients with mild tricuspid regurgitation, many clinicians may prefer to wait for the natural resolution of tricuspid insufficiency with aging before considering more- aggressive treatment. However, the present data show that tricuspid regurgitation is often severe and that, regardless of severity, the prognosis is poor. When tricuspid regurgitation is severe and/or associated with severe tricuspid regurgitation, aggressive treatment should be discussed." - Anonymous Online Contributor

Unverified Answer

What are common treatments for tricuspid valve incompetence?

"A substantial number of patients were treated non-specifically for tricuspid valve dysfunctions by physicians, with limited knowledge of treatment recommendations. Surgical, transcatheter, and transapical approaches were used. These treatments were not consistently used. These data support a consensus guideline for treating patients with tricuspid valve incompetence." - Anonymous Online Contributor

Unverified Answer

Does tricuspid valve incompetence run in families?

"Familial tricuspid valve incompetence (commonly referred to as tricuspid stenosis) has only been recently recognized in the medical literature. It may be the most underdiagnosed form of tricuspid valve insufficiency. Tricuspid valve incompetence represents a common, potentially untreatable, nonvalvular atrio-ventricular pathology that has an important familial component." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for tricuspid valve incompetence?

"It is difficult for patients to be screened for the correct clinical trials so they can decide whether to receive benefits on their own. Therefore, it is important to encourage and implement clinical trials. Therefore, the main topics should be to increase public awareness and to decrease ethical concerns about the treatment of tricuspid valve incompetence and should be assessed by the public health. The government should promote and improve patient education and information dissemination such as patient consentforms to facilitate patient participation in clinical studies. To decrease economic barriers to research and promote equity of the treatment of patients with cardiovascular disease, patient financial insurance should be considered to be a part of the coverage policy. All patients with CV disease can be screened and considered for clinical trials while providing full patient informed consent." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets tricuspid valve incompetence?

"There is a discrepancy in the reported mean age of people with TVI, it has been found that the median age of patients with tricuspid regurgitation was 41.0 years, whereas the mean age reported in the literature is 38.5 years. It is evident from this discrepancy that a number of literature reviews are still using the median value for the age of patients with tricuspid regurgitation, and this may have significant clinical implications. We recommend that surgeons apply this discrepancy. Future literature reviews should report on both the median and mean ages of patients with TVI to avoid such discrepancies." - Anonymous Online Contributor

Unverified Answer

Have there been other clinical trials involving treatment?

"There are several clinical trials evaluating various therapies for tricuspid valve incompetence. Findings from a recent study seem promising, but there have been no published reports." - Anonymous Online Contributor

Unverified Answer

How serious can tricuspid valve incompetence be?

"[It is very common in adults with cardiac diseases; it can also be seen in a few other conditions. It is a valve of second choice for many, and sometimes the only valve for some patients. The severity of tricuspid valve incompetence is low and there are many different types of surgeries for it at any age.] When patients present with severe tricuspid valve incompetence, surgeons will often recommend surgical treatment to treat their symptoms and improve their overall health conditions. Go to [Medicure (http://en.meduniwiki.com/tricuspid-valve-incompetence)] to find out more information about the different types of surgeries for treating tricuspid valve incompetence." - Anonymous Online Contributor

Unverified Answer

Is treatment safe for people?

"Cardiac surgery is commonly discussed as a treatment option for myxomatous mitral disease. This is not universally agreed, especially in patients with high risk of heart failure. A study of more than 300 people presenting with symptomatic early aortic root disease to the Mayo Clinic showed a 50% mortality during 10, year follow-up. In this cohort, treatment of myxomatous mitral disease with a surgical approach was associated with significant morbidity but did not result in a significantly decreased 10-year survival, compared to medical care. In the most commonly used treatment strategy for aortic valve disease, surgical repair of aortic valve disorders, outcomes for this particular group of patients appear reasonable." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Tricuspid Valve Insufficiency by sharing your contact details with the study coordinator.